Browse studies

Find your next paid study

55 recruiting studies matching your filters

A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer

Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are s…

Endocrine TumorsNon-Small Cell Lung CancerOvarian Cancer+4 more

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT03412877

Phase 1

Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, hea…

Sinonasal Neuroendocrine CarcinomaNasopharyngeal CarcinomaEsthesioneuroblastoma+7 more

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)

Phase 2

UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2/3 Neuroendocrine Tumors

This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with…

Neuroendocrine Tumor Grade 2Neuroendocrine Tumors

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Abramson Cancer Center at Penn MedicineNCT04339036

Phase 2

Evaluation of the Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

Background: People with von Hippel-Lindau (VHL) can have problems with a variety of organs, such as the pancreas. The disease can cause tumors of the pancreas…

VHL Pancreatic Neuroendocrine TumorsVon Hippel-Lindau DiseaseNeuroendocrine Tumors

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT04074135

Phase 1

Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors

This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the …

Metastatic Malignant Solid NeoplasmMetastatic MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8+14 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Phase 2

A Phase II Study of Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Background: Small cell carcinoma of the bladder (SCCB) and other high-grade neuroendocrine tumors (HGNET) of the urinary tract are rare but aggressive cancers…

Small Cell Carcinoma of the BladderHigh Grade Neuroendocrine Tumors of the Urinary Tract

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT06228066

Phase 1

An Exploratory Study of [68Ga]Ga-Fibroblast Activation Protein Inhibitor 4 ([68Ga]Ga-FAPI-04) in Patients With High-Grade Neuroendocrine Neoplasms

This early phase I trial determines where and to what degree the tracer \[68Ga\] Ga-FAPI-04 accumulates in normal and cancer tissues in patients with high grad…

Neuroendocrine Tumor

Estimated

~$150 – $3,000

Actual pay is set by the research site.

University of Michigan Rogel Cancer CenterNCT07132645